๐Ÿ’พ Data Updated: 2025 HTS Revision 30 โ€ข Last updated: November 24, 2025

2933.49.26.00 - Other

Details

FieldValue
Unit of Quantitykg
General Rate of Duty6.5%
Special Rate of DutyFree (A+,AU,BH,CL,CO,D, E,IL,JO,K, KR,MA,OM,P, PA,PE,S,SG)
A+ ๐Ÿ‡ฆ๐Ÿ‡ซ ๐Ÿ‡ฆ๐Ÿ‡ด ๐Ÿ‡ง๐Ÿ‡ฏ ๐Ÿ‡ง๐Ÿ‡น ๐Ÿ‡ง๐Ÿ‡ซ ๐Ÿ‡ง๐Ÿ‡ฎ ๐Ÿ‡ฐ๐Ÿ‡ญ ๐Ÿ‡จ๐Ÿ‡ซ ๐Ÿ‡น๐Ÿ‡ฉ ๐Ÿ‡ฐ๐Ÿ‡ฒ ๐Ÿ‡จ๐Ÿ‡ฉ ๐Ÿ‡ฉ๐Ÿ‡ฏ ๐Ÿ‡ช๐Ÿ‡น ๐Ÿ‡ฌ๐Ÿ‡ฒ ๐Ÿ‡ฌ๐Ÿ‡ณ ๐Ÿ‡ฌ๐Ÿ‡ผ ๐Ÿ‡ญ๐Ÿ‡น ๐Ÿ‡ฐ๐Ÿ‡ฎ ๐Ÿ‡ฑ๐Ÿ‡ธ ๐Ÿ‡ฑ๐Ÿ‡ท ๐Ÿ‡ฒ๐Ÿ‡ฌ ๐Ÿ‡ฒ๐Ÿ‡ผ ๐Ÿ‡ฒ๐Ÿ‡ฑ ๐Ÿ‡ฒ๐Ÿ‡ท ๐Ÿ‡ฒ๐Ÿ‡ฟ ๐Ÿ‡ฒ๐Ÿ‡ฒ ๐Ÿ‡ณ๐Ÿ‡ต ๐Ÿ‡ณ๐Ÿ‡ช ๐Ÿ‡ท๐Ÿ‡ผ ๐Ÿ‡ผ๐Ÿ‡ธ ๐Ÿ‡ธ๐Ÿ‡ณ ๐Ÿ‡ธ๐Ÿ‡ฑ ๐Ÿ‡ธ๐Ÿ‡ง ๐Ÿ‡ธ๐Ÿ‡ด ๐Ÿ‡ธ๐Ÿ‡ธ ๐Ÿ‡ธ๐Ÿ‡น ๐Ÿ‡น๐Ÿ‡ฟ ๐Ÿ‡น๐Ÿ‡ฑ ๐Ÿ‡น๐Ÿ‡ฌ ๐Ÿ‡น๐Ÿ‡ป ๐Ÿ‡บ๐Ÿ‡ฌ ๐Ÿ‡ป๐Ÿ‡บ ๐Ÿ‡พ๐Ÿ‡ช ๐Ÿ‡ฟ๐Ÿ‡ฒ
AU ๐Ÿ‡ฆ๐Ÿ‡บ
BH ๐Ÿ‡ง๐Ÿ‡ญ
CL ๐Ÿ‡จ๐Ÿ‡ฑ
CO ๐Ÿ‡จ๐Ÿ‡ด
D ๐Ÿ‡ฆ๐Ÿ‡ด ๐Ÿ‡ง๐Ÿ‡ฏ ๐Ÿ‡ง๐Ÿ‡ผ ๐Ÿ‡ง๐Ÿ‡ซ ๐Ÿ‡จ๐Ÿ‡ป ๐Ÿ‡จ๐Ÿ‡ซ ๐Ÿ‡น๐Ÿ‡ฉ ๐Ÿ‡ฐ๐Ÿ‡ฒ ๐Ÿ‡จ๐Ÿ‡ฎ ๐Ÿ‡จ๐Ÿ‡ฉ ๐Ÿ‡ฉ๐Ÿ‡ฏ ๐Ÿ‡ธ๐Ÿ‡ฟ ๐Ÿ‡ช๐Ÿ‡น ๐Ÿ‡ฌ๐Ÿ‡ฆ ๐Ÿ‡ฌ๐Ÿ‡ฒ ๐Ÿ‡ฌ๐Ÿ‡ญ ๐Ÿ‡ฌ๐Ÿ‡ณ ๐Ÿ‡ฌ๐Ÿ‡ผ ๐Ÿ‡ฐ๐Ÿ‡ช ๐Ÿ‡ฑ๐Ÿ‡ธ ๐Ÿ‡ฑ๐Ÿ‡ท ๐Ÿ‡ฒ๐Ÿ‡ฌ ๐Ÿ‡ฒ๐Ÿ‡ผ ๐Ÿ‡ฒ๐Ÿ‡ฑ ๐Ÿ‡ฒ๐Ÿ‡บ ๐Ÿ‡ฒ๐Ÿ‡ฟ ๐Ÿ‡ณ๐Ÿ‡ฆ ๐Ÿ‡ณ๐Ÿ‡ช ๐Ÿ‡ณ๐Ÿ‡ฌ ๐Ÿ‡จ๐Ÿ‡ฌ ๐Ÿ‡ท๐Ÿ‡ผ ๐Ÿ‡ธ๐Ÿ‡ณ ๐Ÿ‡ธ๐Ÿ‡ฑ ๐Ÿ‡ฟ๐Ÿ‡ฆ ๐Ÿ‡ธ๐Ÿ‡น ๐Ÿ‡น๐Ÿ‡ฟ ๐Ÿ‡น๐Ÿ‡ฌ ๐Ÿ‡บ๐Ÿ‡ฌ ๐Ÿ‡ฟ๐Ÿ‡ฒ
E ๐Ÿ‡ฆ๐Ÿ‡ฌ ๐Ÿ‡ฆ๐Ÿ‡ผ ๐Ÿ‡ง๐Ÿ‡ธ ๐Ÿ‡ง๐Ÿ‡ง ๐Ÿ‡ง๐Ÿ‡ฟ ๐Ÿ‡ป๐Ÿ‡ฌ ๐Ÿ‡จ๐Ÿ‡ผ ๐Ÿ‡ฉ๐Ÿ‡ฒ ๐Ÿ‡ฌ๐Ÿ‡ฉ ๐Ÿ‡ฌ๐Ÿ‡พ ๐Ÿ‡ญ๐Ÿ‡น ๐Ÿ‡ฏ๐Ÿ‡ฒ ๐Ÿ‡ฒ๐Ÿ‡ธ NE ๐Ÿ‡ฐ๐Ÿ‡ณ ๐Ÿ‡ฑ๐Ÿ‡จ ๐Ÿ‡ป๐Ÿ‡จ ๐Ÿ‡น๐Ÿ‡น
IL ๐Ÿ‡ฎ๐Ÿ‡ฑ
JO ๐Ÿ‡ฏ๐Ÿ‡ด
K ๐Ÿ‡ฆ๐Ÿ‡ซ ๐Ÿ‡ฆ๐Ÿ‡ฑ ๐Ÿ‡ฆ๐Ÿ‡ฉ ๐Ÿ‡ฆ๐Ÿ‡ด ๐Ÿ‡ฆ๐Ÿ‡ฎ ๐Ÿ‡ฆ๐Ÿ‡ฌ ๐Ÿ‡ฆ๐Ÿ‡ท ๐Ÿ‡ฆ๐Ÿ‡ฒ ๐Ÿ‡ฆ๐Ÿ‡ผ ๐Ÿ‡ฆ๐Ÿ‡บ ๐Ÿ‡ฆ๐Ÿ‡น ๐Ÿ‡ฆ๐Ÿ‡ฟ ๐Ÿ‡ง๐Ÿ‡ธ ๐Ÿ‡ง๐Ÿ‡ญ ๐Ÿ‡ง๐Ÿ‡ฉ ๐Ÿ‡ง๐Ÿ‡ง ๐Ÿ‡ง๐Ÿ‡พ ๐Ÿ‡ง๐Ÿ‡ช ๐Ÿ‡ง๐Ÿ‡ฟ ๐Ÿ‡ง๐Ÿ‡ฏ ๐Ÿ‡ง๐Ÿ‡ฒ ๐Ÿ‡ง๐Ÿ‡น ๐Ÿ‡ง๐Ÿ‡ด ๐Ÿ‡ง๐Ÿ‡ฆ ๐Ÿ‡ง๐Ÿ‡ผ ๐Ÿ‡ง๐Ÿ‡ท ๐Ÿ‡ฎ๐Ÿ‡ด ๐Ÿ‡ป๐Ÿ‡ฌ ๐Ÿ‡ง๐Ÿ‡ณ ๐Ÿ‡ง๐Ÿ‡ฌ ๐Ÿ‡ง๐Ÿ‡ซ ๐Ÿ‡ง๐Ÿ‡ฎ ๐Ÿ‡จ๐Ÿ‡ป ๐Ÿ‡ฐ๐Ÿ‡ญ ๐Ÿ‡จ๐Ÿ‡ฒ ๐Ÿ‡จ๐Ÿ‡ฆ ๐Ÿ‡ฐ๐Ÿ‡พ ๐Ÿ‡จ๐Ÿ‡ซ ๐Ÿ‡น๐Ÿ‡ฉ ๐Ÿ‡จ๐Ÿ‡ฑ ๐Ÿ‡จ๐Ÿ‡ณ ๐Ÿ‡จ๐Ÿ‡ฝ ๐Ÿ‡จ๐Ÿ‡จ ๐Ÿ‡จ๐Ÿ‡ด ๐Ÿ‡ฐ๐Ÿ‡ฒ ๐Ÿ‡จ๐Ÿ‡ฐ ๐Ÿ‡จ๐Ÿ‡ท ๐Ÿ‡ญ๐Ÿ‡ท ๐Ÿ‡จ๐Ÿ‡พ ๐Ÿ‡จ๐Ÿ‡ฟ ๐Ÿ‡จ๐Ÿ‡ฟ ๐Ÿ‡จ๐Ÿ‡ฎ ๐Ÿ‡จ๐Ÿ‡ฉ ๐Ÿ‡ฉ๐Ÿ‡ฐ ๐Ÿ‡ฉ๐Ÿ‡ฏ ๐Ÿ‡ฉ๐Ÿ‡ฒ ๐Ÿ‡ฉ๐Ÿ‡ด EA ๐Ÿ‡ช๐Ÿ‡จ ๐Ÿ‡ช๐Ÿ‡ฌ ๐Ÿ‡ธ๐Ÿ‡ป ๐Ÿ‡ฌ๐Ÿ‡ถ ๐Ÿ‡ช๐Ÿ‡ท ๐Ÿ‡ช๐Ÿ‡ช ๐Ÿ‡ธ๐Ÿ‡ฟ ๐Ÿ‡ช๐Ÿ‡น ET ๐Ÿ‡ซ๐Ÿ‡ฐ ๐Ÿ‡ซ๐Ÿ‡ด ๐Ÿ‡ซ๐Ÿ‡ฏ ๐Ÿ‡ซ๐Ÿ‡ฎ ๐Ÿ‡ซ๐Ÿ‡ท ๐Ÿ‡ฌ๐Ÿ‡ซ ๐Ÿ‡ต๐Ÿ‡ซ ๐Ÿ‡น๐Ÿ‡ซ ๐Ÿ‡ฌ๐Ÿ‡ฆ ๐Ÿ‡ฌ๐Ÿ‡ฒ ๐Ÿ‡ต๐Ÿ‡ธ ๐Ÿ‡ฌ๐Ÿ‡ช ๐Ÿ‡ฉ๐Ÿ‡ช ๐Ÿ‡ฌ๐Ÿ‡ญ ๐Ÿ‡ฌ๐Ÿ‡ฎ ๐Ÿ‡ฌ๐Ÿ‡ท ๐Ÿ‡ฌ๐Ÿ‡ฑ ๐Ÿ‡ฌ๐Ÿ‡ฉ ๐Ÿ‡ฌ๐Ÿ‡ต ๐Ÿ‡ฌ๐Ÿ‡น ๐Ÿ‡ฌ๐Ÿ‡ณ ๐Ÿ‡ฌ๐Ÿ‡ผ ๐Ÿ‡ฌ๐Ÿ‡พ ๐Ÿ‡ญ๐Ÿ‡น ๐Ÿ‡ญ๐Ÿ‡ฒ ๐Ÿ‡ญ๐Ÿ‡ณ ๐Ÿ‡ญ๐Ÿ‡ฐ ๐Ÿ‡ญ๐Ÿ‡บ ๐Ÿ‡ฎ๐Ÿ‡ธ ๐Ÿ‡ฎ๐Ÿ‡ณ ๐Ÿ‡ฎ๐Ÿ‡ฉ IN ๐Ÿ‡ฎ๐Ÿ‡ท ๐Ÿ‡ฎ๐Ÿ‡ถ ๐Ÿ‡ฎ๐Ÿ‡ช ๐Ÿ‡ฎ๐Ÿ‡ฑ IS ๐Ÿ‡ฎ๐Ÿ‡น ๐Ÿ‡ฏ๐Ÿ‡ฒ ๐Ÿ‡ฏ๐Ÿ‡ต ๐Ÿ‡ฏ๐Ÿ‡ด ๐Ÿ‡ฐ๐Ÿ‡ฟ ๐Ÿ‡ฐ๐Ÿ‡ช ๐Ÿ‡ฐ๐Ÿ‡ฎ KO ๐Ÿ‡ฐ๐Ÿ‡ผ ๐Ÿ‡ฐ๐Ÿ‡ฌ ๐Ÿ‡ฑ๐Ÿ‡ฆ ๐Ÿ‡ฑ๐Ÿ‡ป ๐Ÿ‡ฑ๐Ÿ‡ง ๐Ÿ‡ฑ๐Ÿ‡ธ ๐Ÿ‡ฑ๐Ÿ‡ท ๐Ÿ‡ฑ๐Ÿ‡พ ๐Ÿ‡ฑ๐Ÿ‡ฎ ๐Ÿ‡ฑ๐Ÿ‡น ๐Ÿ‡ฑ๐Ÿ‡บ ๐Ÿ‡ฒ๐Ÿ‡ด ๐Ÿ‡ฒ๐Ÿ‡ฌ ๐Ÿ‡ฒ๐Ÿ‡ผ ๐Ÿ‡ฒ๐Ÿ‡พ ๐Ÿ‡ฒ๐Ÿ‡ป ๐Ÿ‡ฒ๐Ÿ‡ฑ ๐Ÿ‡ฒ๐Ÿ‡น ๐Ÿ‡ฒ๐Ÿ‡ญ ๐Ÿ‡ฒ๐Ÿ‡ถ ๐Ÿ‡ฒ๐Ÿ‡ท ๐Ÿ‡ฒ๐Ÿ‡บ ๐Ÿ‡พ๐Ÿ‡น ๐Ÿ‡ฒ๐Ÿ‡ฝ ๐Ÿ‡ซ๐Ÿ‡ฒ ๐Ÿ‡ฒ๐Ÿ‡ฉ ๐Ÿ‡ฒ๐Ÿ‡จ ๐Ÿ‡ฒ๐Ÿ‡ณ ๐Ÿ‡ฒ๐Ÿ‡ช ๐Ÿ‡ฒ๐Ÿ‡ธ ๐Ÿ‡ฒ๐Ÿ‡ฆ ๐Ÿ‡ฒ๐Ÿ‡ฟ ๐Ÿ‡ฒ๐Ÿ‡ฒ ๐Ÿ‡ณ๐Ÿ‡ฆ ๐Ÿ‡ณ๐Ÿ‡ท ๐Ÿ‡ณ๐Ÿ‡ต ๐Ÿ‡ณ๐Ÿ‡ฑ NE ๐Ÿ‡ณ๐Ÿ‡จ ๐Ÿ‡ณ๐Ÿ‡ฟ ๐Ÿ‡ณ๐Ÿ‡ฎ ๐Ÿ‡ณ๐Ÿ‡ช ๐Ÿ‡ณ๐Ÿ‡ฌ ๐Ÿ‡ณ๐Ÿ‡บ ๐Ÿ‡ณ๐Ÿ‡ซ ๐Ÿ‡ฒ๐Ÿ‡ฐ ๐Ÿ‡ณ๐Ÿ‡ด ๐Ÿ‡ด๐Ÿ‡ฒ ๐Ÿ‡ต๐Ÿ‡ฐ ๐Ÿ‡ต๐Ÿ‡ผ ๐Ÿ‡ต๐Ÿ‡ฆ ๐Ÿ‡ต๐Ÿ‡ฌ ๐Ÿ‡ต๐Ÿ‡พ ๐Ÿ‡ต๐Ÿ‡ช ๐Ÿ‡ต๐Ÿ‡ญ ๐Ÿ‡ต๐Ÿ‡ณ ๐Ÿ‡ต๐Ÿ‡ฑ ๐Ÿ‡ต๐Ÿ‡น ๐Ÿ‡ต๐Ÿ‡ท ๐Ÿ‡ถ๐Ÿ‡ฆ ๐Ÿ‡จ๐Ÿ‡ฌ ๐Ÿ‡ท๐Ÿ‡ช ๐Ÿ‡ท๐Ÿ‡ด ๐Ÿ‡ท๐Ÿ‡บ ๐Ÿ‡ท๐Ÿ‡ผ ๐Ÿ‡ธ๐Ÿ‡ญ ๐Ÿ‡ฐ๐Ÿ‡ณ ๐Ÿ‡ฑ๐Ÿ‡จ ๐Ÿ‡ต๐Ÿ‡ฒ ๐Ÿ‡ป๐Ÿ‡จ ๐Ÿ‡ผ๐Ÿ‡ธ ๐Ÿ‡ธ๐Ÿ‡ฒ ๐Ÿ‡ธ๐Ÿ‡ฆ SA ๐Ÿ‡ธ๐Ÿ‡ณ ๐Ÿ‡ท๐Ÿ‡ธ SE SE ๐Ÿ‡ธ๐Ÿ‡จ ๐Ÿ‡ธ๐Ÿ‡ฑ ๐Ÿ‡ธ๐Ÿ‡ฌ ๐Ÿ‡ธ๐Ÿ‡ฐ ๐Ÿ‡ธ๐Ÿ‡ฎ ๐Ÿ‡ธ๐Ÿ‡ง ๐Ÿ‡ธ๐Ÿ‡ด ๐Ÿ‡ฟ๐Ÿ‡ฆ ๐Ÿ‡ฐ๐Ÿ‡ท ๐Ÿ‡ธ๐Ÿ‡ธ SO SO ๐Ÿ‡ช๐Ÿ‡ธ ๐Ÿ‡ฑ๐Ÿ‡ฐ ๐Ÿ‡ธ๐Ÿ‡ฉ SU ๐Ÿ‡ธ๐Ÿ‡ท ๐Ÿ‡ธ๐Ÿ‡ฏ ๐Ÿ‡ธ๐Ÿ‡ช ๐Ÿ‡จ๐Ÿ‡ญ ๐Ÿ‡ธ๐Ÿ‡พ ๐Ÿ‡ธ๐Ÿ‡น ๐Ÿ‡น๐Ÿ‡ผ ๐Ÿ‡น๐Ÿ‡ฏ ๐Ÿ‡น๐Ÿ‡ฟ ๐Ÿ‡น๐Ÿ‡ญ ๐Ÿ‡น๐Ÿ‡ฑ ๐Ÿ‡น๐Ÿ‡ฌ ๐Ÿ‡น๐Ÿ‡ฐ ๐Ÿ‡น๐Ÿ‡ด TR ๐Ÿ‡น๐Ÿ‡น ๐Ÿ‡น๐Ÿ‡ณ ๐Ÿ‡น๐Ÿ‡ท ๐Ÿ‡น๐Ÿ‡ฒ ๐Ÿ‡น๐Ÿ‡จ ๐Ÿ‡น๐Ÿ‡ป ๐Ÿ‡บ๐Ÿ‡ฌ ๐Ÿ‡บ๐Ÿ‡ฆ ๐Ÿ‡ฆ๐Ÿ‡ช ๐Ÿ‡ฌ๐Ÿ‡ง UN ๐Ÿ‡บ๐Ÿ‡พ ๐Ÿ‡บ๐Ÿ‡ฟ ๐Ÿ‡ป๐Ÿ‡บ ๐Ÿ‡ป๐Ÿ‡ฆ ๐Ÿ‡ป๐Ÿ‡ช ๐Ÿ‡ป๐Ÿ‡ณ ๐Ÿ‡ผ๐Ÿ‡ซ ๐Ÿ‡ต๐Ÿ‡ธ ๐Ÿ‡ช๐Ÿ‡ญ ๐Ÿ‡พ๐Ÿ‡ช ๐Ÿ‡ฟ๐Ÿ‡ฒ ๐Ÿ‡ฟ๐Ÿ‡ผ
KR ๐Ÿ‡ฐ๐Ÿ‡ท
MA ๐Ÿ‡ฒ๐Ÿ‡ฆ
OM ๐Ÿ‡ด๐Ÿ‡ฒ
P ๐Ÿ‡จ๐Ÿ‡ท ๐Ÿ‡ฉ๐Ÿ‡ด ๐Ÿ‡ธ๐Ÿ‡ป ๐Ÿ‡ฌ๐Ÿ‡น ๐Ÿ‡ญ๐Ÿ‡ณ ๐Ÿ‡ณ๐Ÿ‡ฎ
PA ๐Ÿ‡ต๐Ÿ‡ฆ
PE ๐Ÿ‡ต๐Ÿ‡ช
S ๐Ÿ‡จ๐Ÿ‡ฆ ๐Ÿ‡ฒ๐Ÿ‡ฝ
SG ๐Ÿ‡ธ๐Ÿ‡ฌ
Column 2 Rate of Duty15.4ยข/kg + 67.5%
Quota QuantityN/A
Additional DutiesN/A

Overview

This classification, 2933.49.26.00, encompasses "Other" heterocyclic compounds containing a quinoline or isoquinoline ring-system, not further fused, that are specifically intended for use as drugs. This broad category captures pharmaceutical substances falling under the quinoline/isoquinoline family that do not fit into more specific subheadings within this chapter. The classification focuses on the chemical structure and the intended end-use as a medicinal agent.

Distinguishing this subcategory from its sibling, 2933.49.20.00, is crucial for accurate classification. The sibling category specifically lists certain named compounds, such as 5-Chloro-7-iodo-8-quinolinol and its related derivatives. Therefore, 2933.49.26.00 is intended for quinoline or isoquinoline-based drugs that are *not* among those explicitly enumerated in the sibling category. Classification here relies on identifying the drugโ€™s chemical identity and its pharmaceutical application.

As this is a leaf node in the HTS, there are no further subcategories. This means that any compound meeting the criteria of containing a quinoline or isoquinoline ring-system, not further fused, and intended for use as a drug, which is not specifically listed under a more precise subheading, will be classified under 2933.49.26.00. The decisive factor remains the compound's chemical structure and its established pharmaceutical function.

Stay Updated

Join our newsletter to get all updates of the harmonized Tariff Schedule.